Edition:
United States

Vertex Pharmaceuticals Inc (VRTX.O)

VRTX.O on Nasdaq

187.84USD
20 Feb 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$187.84
Open
$186.06
Day's High
$188.64
Day's Low
$185.65
Volume
1,066,275
Avg. Vol
1,556,418
52-wk High
$195.81
52-wk Low
$144.07

Chart for

About

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The... (more)

Overall

Beta: 1.66
Market Cap(Mil.): $48,022.59
Shares Outstanding(Mil.): 255.66
Dividend: --
Yield (%): --

Financials

  VRTX.O Industry Sector
P/E (TTM): 90.86 87.17 36.18
EPS (TTM): 2.07 -- --
ROI: 13.43 10.35 12.67
ROE: 16.60 10.64 13.70

Vertex Pharma boots out COO for 'personal behavior' violations

Vertex Pharmaceuticals Inc said on Wednesday it had terminated the employment of its chief operating officer and interim chief financial officer, Ian Smith, citing "personal behavior" that violated its code of conduct.

Jan 23 2019

UPDATE 1-Vertex Pharma boots out COO for "personal behavior" violations

Jan 23 Vertex Pharmaceuticals Inc said on Wednesday it had terminated the employment of its chief operating officer and interim chief financial officer, Ian Smith, citing "personal behavior" that violated its code of conduct.

Jan 23 2019

Vertex Pharma terminates interim CFO's employment for code violations

Jan 23 Vertex Pharmaceuticals Inc said on Wednesday it had terminated the employment of its chief operating officer and interim chief financial officer, Ian Smith, citing personal behavior that violated its code of conduct.

Jan 23 2019

Vertex posts positive data from cystic fibrosis triple combo trials

Vertex Pharmaceuticals Inc said on Tuesday that its triple combination therapy showed significant improvement in lung function in patients with cystic fibrosis (CF) in two late-stage clinical studies, sending its shares up 5 percent.

Nov 27 2018

REFILE-Vertex posts positive data from cystic fibrosis triple combo trials

Nov 27 Vertex Pharmaceuticals Inc said on Tuesday that its triple combination therapy showed significant improvement in lung function in patients with cystic fibrosis (CF) in two late-stage clinical studies, sending its shares up 5 percent.

Nov 27 2018

Earnings vs. Estimates